Inclusion Criteria:

          -  Histologically or cytologically confirmed localized prostatic adenocarcinoma. Patients
             with primarily neuroendocrine/small cell histology will be excluded.

          -  Patients with high risk or very high risk prostatic adenocarcinoma as defined by NCCN
             criteria.

               -  High risk is defined by NCCN as meeting at least one of the following criteria:

                    -  T3a

                    -  grade group 4 or 5

                    -  PSA > 20

               -  Very high risk is defined by NCCN as meeting at least one of the following
                  criteria:

                    -  T3b-T4

                    -  primary Gleason pattern 5

                    -  2-3 high risk features **> 4 cores with grade group 4 or 5

          -  Willing and able to undergo prostate MRI at baseline, with a measurable prostate
             lesion present.

          -  Planning to undergo radical prostatectomy as primary treatment for localized prostate
             cancer.

          -  At least 18 years of age.

          -  ECOG performance status ≤ 1

          -  Normal bone marrow and organ function as defined below:

               -  Leukocytes ≥ 3,000/mcL

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Platelets ≥ 100,000/mcL

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)

               -  AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN

               -  Estimated glomerular filtration rate eGFR ≥ 30 mL/min/1.73m^2

          -  Agreement to adhere to Lifestyle Considerations throughout study duration

          -  Ability to understand and willingness to sign an IRB approved written informed consent
             document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  Current or previous treatment with SGLT2i or thiazolidinedione.

          -  Currently receiving regularly scheduled systemic steroids in the form of prednisone or
             dexamethasone. Topical steroid ointments or creams for occasional skin rash is
             allowed.

          -  A history of other malignancy with the exceptions of malignancies for which all
             treatment was completed at least 2 years before registration with no evidence of
             disease and locally treated skin squamous or basal cell carcinoma.

          -  History of stroke or transient ischemic attack in the last 5 years.

          -  Patients with type 1 diabetes mellitus will be excluded.

          -  HbA1c > 10%, unless approved by endocrinologist. No patients with insulin-requiring
             diabetes mellitus will be allowed.

          -  Currently receiving any other investigational agents.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to dapagliflozin.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, peripheral arterial disease, ketoacidosis, severe kidney disease
             (estimated glomerular filtration rate eGFR < 30 mL/min/1.73m2), symptomatic
             hypotension, and chronic/frequent urinary tract infections or yeast infections.

          -  Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or
             they have a history of AIDS-defining opportunistic infection within the 12 months
             prior to registration. Concurrent treatment with effective ART according to DHHS
             treatment guidelines is recommended.

          -  Any evidence of pelvic instrumentation (i.e. hip arthroplasty) that would obscure
             and/or limit prostate MRI evaluation at the discretion of the investigator, or any
             type of medical device that would be incompatible with MRI imaging.